PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Phenotype | C0005940|bone disease |
| Sentences | 11 |
| PubMedID- 20151162 | Background: pain relief is an important treatment goal for breast cancer patients with metastatic bone disease and treatment should be associated with a low rate of side effects. |
| PubMedID- 26197890 | The frequency of proteinuria in breast cancer patients with metastatic bone disease receiving intravenous ibandronate was similar to those receiving placebo or no clinical relevant changes from baseline in 2 randomized trials [10, 21]. |
| PubMedID- 20465790 | Markers of collagen synthesis have been evaluated as bone markers for metastatic bone disease due to breast cancer. |
| PubMedID- 20574672 | Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. |
| PubMedID- 21197465 | The protein is also important for metastatic bone disease of prostate and breast cancers, while runx2 may have both tumor suppressive and oncogenic roles in bone morphogenesis. |
| PubMedID- 23239200 | Therefore, pqip, and its novel derivatives that are currently in advanced clinical development for the treatment of a number of solid tumors, may be of value in the treatment of osteolytic bone disease associated with breast cancer. |
| PubMedID- 24392878 | Purpose: to evaluate the efficacy of radionuclide palliative therapy (rpt) in women suffering from painful metastatic bone disease (mbd) due to breast cancer (brca), and to investigate the possible relationship between the rpt efficacy and cytokines levels. |
| PubMedID- 20136578 | Renal function changes and nhs resource use in breast cancer patients with metastatic bone disease treated with iv zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. |
| PubMedID- 26514370 | This review examines the pathophysiology of bone loss and gives guidelines for the management of bone disease in women with breast cancer. |
| PubMedID- 25505750 | A phase 1 trial has been reported for 15 hormone refractory prostate cancer patients and 10 breast cancer patients, all with metastatic bone disease [36]. |
| PubMedID- 24528599 | In contrast to myeloma bone disease, the role of dkk-1 in breast cancer and prostate cancer is less clear. |
Page: 1